Antibody Therapy for COVID 19 – BAMLANIVIMAB (Eli Lilly’s Monoclonal Antibody) || And 6 other updates)
UPDATE: Eli Lilly’s Bamlanivimab now granted FDA EUA.
In this video, I discuss updates with the COVID surge here, controlling the COVID Pandemic, Immunity to the Coronavirus, possible Coronavirus treatments on the horizon, and more.
00:00 Top 7 COVID Updates
01:17 Surge in COVID Cases
02:24 Coronavirus Pandemic Control
03:45 Doctors Inflate Numbers
05:31 Coronavirus Immunity
06:34 COVID Vaccine
07:23 Aspirin for COVID
08:24 Coronavirus Treatment (Bamlanivimab and more)
And as if COVID by itself is not bad enough, it has a domino effect on the rest of our society. It’s not just the economy that suffers. It’s also the rest of healthcare in general that suffers. Not to mention increased rates of depression and suicide deaths during these times. If hospitals are overwhelmed, guess what happens to the care of other patients who don’t have COVID?
Elective surgeries are being put off for things like heart surgery, hip replacement, and more. Also, who wants to go to a doctor’s office or an ER during these times and possibly get COVID? It’s not like we don’t know how to get this pandemic under control. It can be done. Look at how well other countries handled it and how well they are doing. And how well their economies are doing. Australia. New Zealand. South Korea. Taiwan. What do all of these countries have in common? Testing, contact tracing, quarantine, distancing, and masks.
This pandemic will only worsen in the next couple of months, and more and more hospitals will be overwhelmed. The difference between what’s happening now compared to what happened during the previous spike in cases is that the entire country is a hotspot. And because it is so widespread, we will soon reach a breaking point in our hospitals and the number of healthcare workers.
In all likelihood, one of three things is going to happen. There will be a federal mask mandate because not enough people are wearing masks when they should be. If this does not happen, there will likely be a shutdown of most of the country.
Now some people say doctors are inflating the numbers. So this is not true. Part of my job as an ICU physician is to complete a death certificate, and I have to write the primary cause of death and secondary causes of death. There is usually a chain of events that causes someone to die. Many times, multiple contributing factors lead to someone’s death, but usually, we know the primary cause of death. And with COVID, it’s usually pretty straight forward. Also, regarding the claim that doctors get paid more based on the diagnosis? It’s a lie, plain and simple.
Are people immune to the virus after they are infected? Antibodies are made by the body in response to a given infection or a vaccine. Usually, antibodies protect someone from future infection, and so they are called “neutralizing antibodies.” Researchers at Mount Sinai’s Health System between March and October looked at the antibody responses of more than 30,000 people who tested positive for covid 19. These people who had Coronavirus had either mild or moderate illness.
In the study, they described their antibody responses as either low, moderate, or high. More than 90% had moderate to high levels of neutralizing antibodies to the virus’s e spike proteus, and the response was maintained for at least 5 months. So can you get infected with Coronavirus twice? Based on this, probably not. If it does occur, it’s the exception, not the rule. And this study also has implications when it comes to immunity from a vaccine. It’s likely that a vaccine will provide immunity, but for how long is another question. Based on this study, the answer is most likely at least 5 months.
There are over 70 monoclonal antibody treatments for COVID 19 in various stages of development. The two that have the most potential right now are the ones made by Eli Lilly and Regeneron. Both of these companies have already applied for FDA emergency use authorizations. Eli Lilly recently signed a $375 million deal with the government for 300,000 vials of this monoclonal antibody, called Bamlanivimab. A recent study in NEJM looked at Bamlanivimab, and it seemed to decrease the risk of hospitalization and ease some symptoms in this phase 2 trial that involved over 400 patients with either mild to moderate COVID 19.
In this RCT, less than 2% of patients who received Bamlanivimab had symptoms progress enough to the point of requiring hospitalization or a trip to the ER. For those who received a placebo, it was 6%. Patients in higher-risk categories – defined ae obese or older than 6s – 4% who got the treatment were hospitalized, compared to 15% in the placebo group. The study’s e primary goal was to see if the treatment eliminated the virus by day 11, which it did for the vast most.